To the question of complex treatment of endometriosis

Authors

  • Н. Ф. Захаренко Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine, Ukraine
  • Н. В. Коваленко Kyiv City Hospital number 9, Ukraine
  • І. П. Маноляк Institute of Pediatrics, Obstetrics and Gynecology of the NAM S of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.23.28-33

Keywords:

endometriosis, antiproliferative treatment, immunohistochemical studies, Epigalin

Abstract

Work on improving the quality of antiproliferative treatment of endometriosis with regard morphological and immunohistochemical data was performed.

At the first phase of the study the activity of proliferation markers and apoptosis markers in patients with various forms of endometriosis were studies: in 35 patients with internal endometriosis (adenomyosis), 52 patients with external genital endometriosis and 19 patients with extragenital endometriosis. As a result, it was found that in the lesions of endometriosis there are low apoptosis, high cell proliferative activity and proliferative endometrium type is prevalent (endometrial hyperplasia).

At the second phase of the study antiproliferative properties of drug Epigalin in the treatment of endometriosis were assessment. 38 patients with adenomyosis and marked pain syndrome participated in a study: 18 patients received dienogest and 20 patients received dienogest and administered Epigalin. The result revealed that Epigalin use in the treatment of endometriosis allows controlling proliferative potential of the endometrium cells.

Author Biographies

Н. Ф. Захаренко, Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine

MD, chief researcher at the Endocrine Gynecology Department

Н. В. Коваленко, Kyiv City Hospital number 9

Doctor of the Gynecological Department

І. П. Маноляк, Institute of Pediatrics, Obstetrics and Gynecology of the NAM S of Ukraine

Junior researcher at the Endocrine Gynecology Department

References

  1. Adamyan, L.V., Kulakov, V.I. Endometriosis. Moscow. Medicine (1998): 317 p.
  2. Kudrina, E.A., Ishchenko, A.I., Gadaeva, I.V., Shadyev, A.H., Kogan, E.A. “Molecular and biological characteristics of external genital endometriosis.” Obstetrics and gynecology, 6(2000): 24–27.
  3. Sidorova, I.S., Kogan, E.A., Zayratiants, O.V., Unanian, A.L., Levakov, S.A. “A new look at the nature of endometriosis (adenomyosis).” Obstetrics and Gynecology, 3(2002): 32–38.
  4. Tatarchuk, T.F., Kalugina, L.V. “Issue of prevention and treatment of hormonehyperproliferative diseases in women.” Women's Health, 7(2013): 51–57.
  5. A shok, B.T., Chen, Y.G., Liu, X., Garikapaty, V.P., Seplowitz, R., et al. “Multiple molecular targets of indole-3carbinol, a chemopreventive anti-estrogen in breast cancer.” Eur J Cancer Prev, 11(2002): 86–93.
  6. A uborn, K.L., Fan, S., Rosen, E.M., Goodwin L., et al. “Indole-3-carbinol is a negative regulator of estrogen.” J Nutr, 133(2003): 2470–2475.
  7. C hatterji, U., Riby, J.E., Taniguchi, Т., Bjeldanes, E.X., et al. “Indole-3-carbinol stimulates transcription of the interferon gamma receptor 1 gene and augments interferon responsiveness in human breast cancer cells.” Carcinogeneses, 1 (Vol. 1) (2004): 119–1128.
  8. Darai, E., Detchev, R., Hugol, D., Quang, N. T. “Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.” Hum Reprod, 18(2003): 1681–1685.
  9. Dmowski, W.P., Ding, J., Shen, J., Rana, N., Fernandez, B.B., Braun D.P. “Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis.” Hum Reprod, 16(2001): 1802–1808.
  10. Firestone, G.L., Bjeldanes, L.F. “Indole-3-carbinol and З-З-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp 1 transcription factor interactions.” J Nutr, 133(2003): 2448–2455.
  11. M asuda, M., Suzuki, M., Lim, J.T.E., Weinstein, I.E. “Epigallocatechin-3-gallate inhibits activation of HER -2/neu and downstream signaling pathways in human heat and neck and breast carcinoma cells.” Clin Cancer Res, 9(2003): 3486–3491.
  12. R ahman, K.M., Aranha, O., Sarkar, F.H. “Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epitelial cells.” Nutr Cancer, 45(2003): 101–112.
  13. R eed, G.A., Peterson, K.S., Smith, H.J., Gray, J.C., Sullivan, D.K., et al. “A phase I study of indole-3-carbinol in women: tolerability and effects.” Cancer Epidemiol Biomarkers Prev, 8(2005).
  14. Scholzen, Т., Gerdes, J. “The Ki-67 protein: from the know and the unknown.” J Cell Physiol, 3(2000): 311–312.
  15. Thangapazham, R.L., Singh, A.K., Sharma, A., et.al. “Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.” Cancer Lett, 8(2007): 832–841.

Downloads

Published

2015-06-24

How to Cite

Захаренко, Н. Ф., Коваленко, Н. В., & Маноляк, І. П. (2015). To the question of complex treatment of endometriosis. REPRODUCTIVE ENDOCRINOLOGY, (23), 28–33. https://doi.org/10.18370/2309-4117.2015.23.28-33

Issue

No. 23 (2015)

Section

Gynecology

License

Copyright (c) 2015 Н. Ф. Захаренко, Н. В. Коваленко, І. П. Маноляк

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.